CReATe Biorepository

Biomarker development is a high priority for the amyotrophic lateral sclerosis (ALS) and related disorders community. While biomarkers may add value in facilitating earlier disease diagnoses, the most pressing need is for biomarkers that might aid therapeutic development. There is increasing recognition that the development and validation of such biomarkers will require multi-center collaborative undertakings in which biological samples are collected, stored, and processed in a harmonized manner from patients who are followed longitudinally with careful collection of phenotypic data.

The CReATe Consortium is establishing a repository of biological samples collected from patients participating in the Phenotype-Genotype-Biomarker (PGB) (NCT02327845), Phenotype-Genotype and Biomarkes 2 (PGB2) (NCT04875416), and TRIAL READY (NCT03912987) protocols. These studies include patients with ALS, ALS-frontotemporal dementia (ALS-FTD), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), hereditary spastic paraplegia (HSP), multisystem proteinopathy (MSP), and controls. The biorepository contains a broad array of biological samples collected from every participant at each study visit according to the schedule summarized in the table below.

Anticipated Schedule of Biological Sample Collection/Storage

Biological samples are collected, processed, and stored using a strict set of standard operating procedures (SOPs). For a copy of these SOPs, click here.